Vaccination and the respiratory tract - What should we know?;Vacinas e o trato respiratório - O que devemos saber?

Jornal de Pediatria

Volumn 78, Issue SUPPL. 2, 2002, Pages

  Farhat, Calil Kairalla ^a,d   Cintra, Otávio Augusto Leite ^b   Tregnaghi, Miguel W ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital Infantil Municipal de Cordoba   (Argentina)

^d NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE VACCINE; INFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE;

FACTUAL DATABASE; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS; MEDICAL LITERATURE; MEDLINE; NONHUMAN; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIA; VACCINATION;

EID: 0036866368     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/jped.898     Document Type: Review

References (94)

1. American Academy of Pediatrics. Influenza. In: Pickering LK, editor. 2000 Red Book: Report of the Committee on Infectious Diseases. 25 Ed. Elk Grove Village, (IL): American Academy of Pediatrics; 2000.p.351-9.
2. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: A randomized controlled trial. Lancet 2000;355:93-7.
3. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals. JAMA 1999;281(10):908-13.
4. Yassi A, Kettner J, Hammond G et al. Effectiveness and cost-benefit of an influenza vaccination program for health care workers. Can J Infect Dis 1991;2:101-8.
5. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997;39:408-14.
6. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med 1995;333:889-93.
7. Centers for Disease Control - Prevention and Control of Influenza. Recommendations of the ACIP. MMWR Morb Mortal Wkly Rep 2002;51:1-31.
8. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991;145:445-8.
9. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9.
10. Committee on Infectious Diseases - American Academy of Pediatrics. Recommended Childhood Immunization Schedule - United States, 2002. Pediatrics 2002;109:162-4.
11. Garpenholt O, Svante H, Fredlund H, Bodin L, Olcén P. Epiglotittis in Sweden before and after introduction of vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999;18:490-3.
12. Mulholland K. Evaluation of vaccines to prevent childhood pneumonia: Lessons relevant to planning tuberculosis vaccine trials. Clin Infect Dis 2000;30 Suppl 3:206-9.
13. Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, etal. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999;18:1060-4.
14. a ed. Elk Grove Village, (IL): American Academy of Pediatrics, 2000.p.483-7.
15. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
16. McCracken GH Jr. Etiology and Treatment of pneumonia. Pediatr Infect Dis J 2000;19:373-377.
17. Brandileone MCC. Distribuiçãao de sorotipos, resistência antimicrobiana e perfil molecular de Streptococcus Pneumoniae isolado de doença invasiva no Brasil: 1993 a 1998 [dissertação]. São Paulo: Escola Paulista de Medicina; 1999.
18. World Health Organization. The world health report 1998. WHO, 62. Geneva: 1998.
19. Leowsky J. Mortality from acute respiratory infections in children under 5 years of age: Global estimate. World Health Statistics Quarterly-Rapport Trimestriel de Statistiques Sanitaries Mondiales 1986;39:138-44.
20. World Health Organization. Acute respiratory infections: progress and current status of the programme. WHO/RSD 1986;86.30 Rev 1.
21. World Health Organization Scientific Group: Viral Respiratory Diseases. WHO Technical Report Series, 642. Geneva: 1980.
22. Arruda E, Geist FC, Mcauliffe MI, Hayden FG. Viral respiratory tract illnesses in a developing tropical area - Prospective studies in Gonçalves Dias, Fortaleza, Brazil. In: At the Edge of Development - Health Crises in a Transitional Society. Guerrant RL, De Souza MA, Nations MK, editors. Durham, (NC): Carolina Academic Press; 1996.p.203-23.
23. Shaan F, Steinhoff MC. Vaccines for children in rich and poor countries. Lancet 1999;354:7-11.
24. a Ed. Philadelphia: WB Saunders; 1998.p.1464-82.
25. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline childhood Haemophilus influenzae type b (Hib) disease in the Hib Vaccine era. JAMA 1993;1993:221-6.
26. Greenwood BM. Epidemiology of acute lower respiratory tract infections, especially those due to Haemophilus influenzae type b, in The Gambia, West Africa. J Infect Dis 1992;165Suppl 1:26-28.
27. Hugosson S, Olcen P, Ekedahl C. Acute epiglottitis: Aetiology, epidemiology and outcome in a population before large-scale Haemophilus influenzae type b vaccination. Clin Otolaryngol 1994;19:441-5.
28. Klein JO. Role of nontypeable Haemophilus influenzae in pediatric respiratory tract infections. Pediatr Infect Dis J 1997;16 Suppl 2: 5-8.
29. Heath PT, Booy R, Azzopardi HJ, Slack MPE, Fogarty J, Moloney AC, et al. Non-type b Haemophilus influenzae disease: Clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J 2000;20:300-5.
30. Peltola H,Terhi K, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992;340:592-4.
31. st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17.
32. Mulholland K. Evaluation of vaccines to prevent childhood pneumonia: Lessons relevant to planning tuberculosis vaccine trials. Clin Infect Dis 2000;30 Suppl 3:206-9.
33. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomized trial of Haemophilus influenzae type-b tetanus protein conjugated vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7.
34. Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999;18:1060-4.
35. Garpenholt O, Svante H, Fredlund H, Bodin L, Olcen P. Epiglotittis in Sweden before and after introduction of vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999;18:490-3.
36. a Ed. Elk Grove Village, (IL): American Academy of Pediatrics; 2000.p.56-66.
37. a ed. New York, (NY): Churhill Livingstone; 1997.p.911-42.
38. Barker WH. Excess pneumonia and influenza An associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986;76:761-5.
39. Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NA, et al. Influenza vaccine effectiveness in preventing hospitalizations for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307.
40. Gorse GJ, Otto EE, Daughaday CC, Newman FK, Eickhoff CS, Powers DC, et al. Influenza virus vaccination of patients with chronic lung disease. Chest 1997;112:1221-33.
41. Ljungman P, Andersson J, Aschan J, Barholt L, Ehrnst A, Johansson M, et al. Influenza A in immunocompromised patients. Clin Infect Dis 1993;17:244-7.
42. Centers For Disease Control and Prevention - Recommendations and reports. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2001;52:RR-9.
43. Neuzil KM, Mellen BG, Wright PF, Mitchel JR, Griffin MR. The effect of influenza on hospitalizations, outpatients visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-31.
44. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-4.
45. a ed. Rio de Janeiro: Atheneu Editora; 2000.p.495-516.
46. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski PA. The efficacy of influenza vaccine in elderly persons. A meta-analisys and review of the literature. Ann Intern Med 1995;123:518-27.
47. Nichol KL, Margolis KL, Wurenma J, Sternberg TV. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
48. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-12.
49. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N. Engl. J Med. 1973;288:498-505.
50. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Knipe DM, Howley PM, editores. Virology. Philadelphia, (PA): Lippincott Williams & Wilkins; 2001. p. 1443-85.
51. Simoes EAF. Respiratory syncytial virus infection. Lancet 1999;354:847-52.
52. Nascimento JP, Siqueira MM, Sutmoller F, Krawczuk MM, De Farias V, Ferreira, et al. Longitudinal study of acute respiratory diseases in Rio de Janeiro: Occurrence of respiratory viruses during four consecutive years. Rev Inst Med Trop Sao Paulo 1991;33:287-96.
53. Vieira SE, Stewien KE, Queiroz DA, Durigon EL, Torok TJ, Anderson LJ, et al. Clinical patterns and seasonal trends in respiratory syncytial virus hospitalizations in Sao Paulo, Brazil. Rev Inst Med Trop São Paulo 2001;43:125-31.
54. Cintra OAL, Owa MA, Machado AA, Cervi, MC, Figueiredo LTM, Rocha GM, et al. Occurrence and severity of infections caused by subgroup A and B respiratory syncytial virus in children in southeast Brazil. J Med Virol 2001;65:408-12.
55. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6.
56. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, ethnic group, and maternal antibody level. J Pediatr 1981;98:708-15.
57. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6.
58. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion. Pediatr Infect Dis J 1999;18:223-31.
59. Cintra OAL, Arruda E. Respiratory viral infections in immunocompromised patients. Medicina Ribeirão Preto, 1999;32:129-37.
60. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34.
61. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: A systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 2001;20:954-60.
62. Falsey AR, Walsh EE. Respiratory syncytial virus infections in adults. Clin Microbiol Rev 2000;13:371-84.
63. Prevent Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
64. Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infections in high-risk infants. Pediatrics 1998;102:531-3.
65. Committee on Infectious Diseases and Committee on Fetus and Newborn - American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-16.
66. Sorrentino M, Powers T. Effectiveness of palivizumab: Evaluation of outcomes from the 1998 to 1999 RSV season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000;19:1068-71.
67. Joffe S, Ray GT, Escobar GJ Black SB, Liew TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-22.
68. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immunoglobulin: Decision and costs. Pediatr Pulmonol 2001;32:20-8.
69. Stevens TP, Sinkem RA, Hall CB, Maniscalvo WM, McConnchie KM. Respiratory syncytial virus and preterm infants born at 32 weeks' gestation orearlier: Hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61.
70. a Ed. Philadelphia: WB Saunders; 1998.p.273-84.
71. MacLeod CM, Hodges RG, Heidelberger M, Bernard WG. Prevention ofpneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-65.
72. World Health Organization. Programme for the control of acute respiratory infections: Pneumococcal conjugate vaccines: Report WHO/ARI/94.34. In: WHO Meeting, Geneva, Switzerland, 1994.
73. Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis 1986;5:247-52.
74. CDC. Progress toward elimination of Haemophilus influenzae type b among infants and children. United States, 1987-1993. MMWR Morb Mortal Wkly Rep 1994;43:144-8.
75. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165 Suppl 1:49-52.
76. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-6.
77. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci 1999;354:777-85.
78. CDC. Drug resistant Streptococcus pneumoniae: Kentucky and Tennessee. 1993. MMWR Morb Mortal Wkly Rep 1994;43:23-5.
79. Froom J, Culpepper L, Grob P, Bartelds A, Bowers P, Bridges-Webb C, et al. Diagnosis and antibiotic treatment of acute otitis media: Report from International Primary Care Network. BMJ 1990;300:582-6.
80. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:337-42.
81. Bruyn GA, van Furth R. Pneumococcal polysaccharide vaccines: Indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis 1991;10:897-910.
82. McIntyre P. Epidemiology and prevention of pneumococcal infections. Curr Opin Pediatr 1997;9:9-13.
83. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-24.
84. Hess T. Pneumococcal vaccination: Yes or no? Schweiz Med Wochenschr 1998;128:1096-103.
85. Flo RW, Solberg CO. Pneumococcal vaccine. Tidsskr Nor Laegeforen 1998;118:3799-802.
86. Eskola J, Takala AK, Kilpi TM, Lankinen KS, Kayhty H. Clinical evaluation of new pneumococcal vaccines: The Finnish approach. Dev Biol Stand 1998;95:85-92.
87. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-16.
88. Tregnaghi M, Ruttimann R, Baudagna A. y col. Inmunidad y reactogenicidad de una vacuna anti Neumocócica Undecavalente conjugada (11 Pn-PD) aplicada en esquema primario a niños sanos. 40 Congreso Argentino de Infectología Pediátrica; 29 de maio a 1 de junho de 2002; Buenos Aires, Argentina. Abstract número 21.
89. 197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-63.
90. 197 in United States infants. Pediatrics 1998;101(4 Pt 1):604-11.
91. Black S, Shinefield HR, Fireman B, et al. Efficacy against Pneumonia of heptavalent conjugate Pneumococcal Vaccine (Wyeth Lederle) in 37.868 infants and children: Expanded Data analysis including duration of protection. ISPPD. 3rd International Symposium on Pneumococci and Pneumococcal Diseases; 5 a 8 de maio de 2002; Anchorage, Alaska.
92. Tregnaghi M, Ceballos A, Ruttimann R, et al. Epidemiologic Surveillance of Pneumococcal Disease in children less than 2 years of age in Córdoba Argentina. ISPPD. 3rd International Symposium on Pneumococci and Pneumococcal Diseases; 5 a 8 de maio de 2002; Anchorage, Alaska.
93. Regueira M, Pace J, Bonfiglio R. et al. Invasive Streptococcus pneumoniae Isolates from Argentinian Children: Serotypes. Families of pneumococcal surface protein A (PspA), and genetic diversity. ISPPD. 3rd International Symposium on Pneumococci and Pneumococcal Diseases; 5 a 8 de maio de 2002; Anchorage, Alaska.
94. Ogunniyi D, Graham R, Woodrow M, et al. Combinations of Pneumococcal Virulence Proteins as potential vaccines against infections by Streptococcus pneumoniae. ISPPD. 3rd International Symposium on Pneumococci and Pneumococcal Diseases; 5 a 8 de maio de 2002; Anchorage, Alaska.